<- Go Home
MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Market Cap
$97.8M
Volume
1.2M
Cash and Equivalents
$145.6M
EBITDA
-$92.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$39.0M
Profit Margin
25.30%
52 Week High
$5.77
52 Week Low
$0.99
Dividend
N/A
Price / Book Value
1.24
Price / Earnings
-1.74
Price / Tangible Book Value
1.24
Enterprise Value
-$18.9M
Enterprise Value / EBITDA
0.22
Operating Income
-$99.5M
Return on Equity
60.25%
Return on Assets
-26.29
Cash and Short Term Investments
$154.1M
Debt
$37.5M
Equity
$79.1M
Revenue
$154.1M
Unlevered FCF
-$40.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium